Sioux develops unique system for more precision in diagnostics
Tissue dissection, even in large-scale commercial labs, remains a manual, labor-intensive process with risk of errors and cross-contamination. The Xyall solution provides the missing link, helping to provide reliable diagnostic test results for cancer patients and enabling personalized treatment tailored to the patient's needs.
Guido du Pree, CEO Xyall: 'This development requires enormous expertise in technological areas such as optics, Artificial Intelligence, medical robotics and data processing. The strategic partnership with Sioux was a logical step for us, they have all the knowledge and experience to accelerate our innovation.'
The first system is now undergoing its final test run before being shipped to the United States, where it will be used in one of the largest laboratories there.
Precision medicine is in the process of being revolutionized - providing doctors and patients with the highest quality information about the patient's health. Guido du Pree: "However, using tissue dissection to enable molecular profiling is still a labor-intensive, subjective process. Our technology is changing the way this is done - providing greater accuracy, consistency and overall improved quality control.
In addition to the new large-scale, industrial system, Xyall and Sioux Technologies are developing a smaller, table-top version for hospital-based molecular pathology laboratories. Guido du Pree: 'Global shortages of experienced pathology staff are already putting laboratories under pressure. The Xyall solution offers a solution and helps laboratories to make more efficient use of existing, and increasingly scarce, staffing levels.
Investing in medical innovation
Thanks to scientific research and medical innovations such as the Xyall HT system, more and more people are surviving cancer. Yet, every year, some 45,000 people die from this disease in the Netherlands alone. Therefore it remains crucial to invest in methods to better detect and treat cancer. Therefore Sioux is also involved in Xyall as an investor.